Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Fallopian Tube Cancer Clinical Trial

Official title:

A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00390234
• Other study ID #: NCI-2009-00177
• Secondary ID: PHL-051CDR000050
• Status: Completed
• Phase: Phase 2
• First received: October 18, 2006
• Last updated: December 3, 2015
• Start date: September 2006
• Est. completion date: August 2013

Study information

• Verified date: May 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This phase II trial is studying how well ziv-aflibercept works in treating patients with locally advanced, unresectable or metastatic gynecologic soft tissue sarcoma. Ziv-aflibercept may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Description:

PRIMARY OBJECTIVES:

I. To assess the objective response of recurrent or metastatic gynecologic soft-tissue sarcomas to VEGF-Trap (ziv-aflibercept).

II. To assess the incidence of disease stabilization, as measured by 6-month progression-free survival, in patients with recurrent or metastatic gynecologic soft-tissue sarcomas treated with VEGF-Trap.

SECONDARY OBJECTIVES:

I. To assess time-to-progression and overall survival in patients with recurrent or metastatic gynecologic soft-tissue sarcoma treated with VEGF-Trap.

• As of 24 October 2012, overall survival follow-up is to be discontinued for the one remaining patient on long term follow-up, who has been off protocol therapy for at least 3 years. Time to progression and median survival times have been based on the currently available data.

II. To assess the toxicity associated with VEGF-Trap in patients with recurrent or metastatic gynecologic soft-tissue sarcoma.

III. To characterize the population pharmacokinetics of VEGF-Trap and to explore for demographic and clinical covariates

OUTLINE: This is an open-label, multicenter study.

Patients are stratified according to histology (uterine leiomyosarcoma vs malignant mixed mullerian tumor/carcinosarcoma). Patients receive ziv-aflibercept over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood collection at baseline, every 8 weeks during treatment, and 60 days after completion of study treatment for population pharmacokinetic analysis using enzyme-linked immunosorbent assay (ELISA).

After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 63
• Est. completion date: August 2013
• Est. primary completion date: September 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically/cytologically confirmed soft tissue sarcoma of gynecologic tract including 1 of the following subtypes: uterine leiomyosarcoma, malignant mixed mullerian tumor/carcinosarcoma, disease originating in ovary/fallopian tube allowed

• Locally advanced/unresectable/metastatic disease

• Previously treated disease must have radiographic/clinical evidence of PD

• Measurable disease-at least 1 lesion in at least 1 dimension (longest diameter) as >=20mm with conventional techniques or as >=10mm with spiral CT scan

• Indicator lesions may not have been previously treated with surgery/radiotherapy/radiofrequency ablation unless PD has been confirmed

• ECOG PS 0-2 OR Karnofsky PS 60-100%

• Life expectancy>=3 months

• WBC>=3,000/mm^3

• Absolute neutrophil count>=1,500/mm^3

• Platelet count>=75,000/mm^3

• Bilirubin=<1.5xULN

• AST and ALT=<3xULN

• INR=<1.5 (unless on warfarin)

• Creatinine=<1.5xULN OR creatinine clearance>=60 mL/min

• Urine protein<1+ by dipstick OR 24-hour urine protein<500 mg OR urine protein:creatinine ratio<1

• Not pregnant/nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for =6 months after treatment - No other active malignancy within past 5 years except adequately treated cervical carcinoma in situ/nonmelanoma skin cancer

• No known hypersensitivity to Chinese hamster ovary cell products/other recombinant human antibodies

• No history of allergic reactions attributed to compounds of similar chemical/biological composition to study agents

• No serious/nonhealing wound/ulcer/bone fracture

• No abdominal fistula/gastrointestinal perforation/bowel obstruction/intraabdominal abscess within past 28 days

• No significant traumatic injuries within past 28 days

• No evidence of bleeding diathesis/coagulopathy

• No uncontrolled intercurrent illness including but not limited to: Ongoing/active infection, psychiatric illness or social situations that would preclude study compliance

• <=2 prior cytotoxic chemotherapy regimen for recurrent, locally advanced or metastatic disease

• Recovered from prior therapy

• No prior antiangiogenic agent

Exclusion Criteria:

• < 4weeks since prior chemotherapy (<6 weeks for nitrosoureas/carmustine/mitomycin C), prior investigational treatment, radiotherapy and major surgery/open biopsy

• 1 week since prior core biopsy

• 1 month since prior thrombolytic agents

• Concurrent full-dose anticoagulants with INR>1.5 allowed if: In-range INR (usually between 2-3) on stable dose of oral anticoagulant or low molecular weight heparin,

• OR; For patients on warfarin, the upper target for INR is =3 No active bleeding/pathological condition that carries a high risk of bleeding (e.g. tumor invading major vessels/known varices)

• No evidence of CNS disease including primary brain tumor/brain metastasis

• No other concurrent investigational agents - No concurrent major surgery

• No concurrent combination antiretroviral therapy for HIV-positive patients

• Clinically significant cardiovascular disease including:

• Cerebrovascular accident within past 6 months,

• Uncontrolled hypertension defined as BP>150/100mmHg OR systolic BP>180mmHg if diastolic BP<90 mmHg, on =2 repeated determinations on separate days within past 3 months,

• OR; Antihypertensive medications allowed as long as dose and number of antihypertensive medications have not increased within past 2 weeks, Myocardial infarction, coronary artery bypass graft, or unstable angina within past 6 months, OR;

• OR; NYHA class III-IV congestive heart failure, serious cardiac arrhythmia requiring medication, or unstable angina pectoris within past 6 months, Clinically significant peripheral vascular disease within past 6 months

• OR; pulmonary embolism, deep vein thrombosis, or other thromboembolic event within past 6 months

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinosarcoma
• Fallopian Tube Cancer
• Female Reproductive Cancer
• Leiomyosarcoma
• Mixed Tumor, Mullerian
• Neoplasms, Glandular and Epithelial
• Ovarian Carcinosarcoma
• Ovarian Neoplasms
• Ovarian Sarcoma
• Recurrent Ovarian Epithelial Cancer
• Recurrent Uterine Sarcoma
• Sarcoma
• Stage III Ovarian Epithelial Cancer
• Stage III Uterine Sarcoma
• Stage IV Ovarian Epithelial Cancer
• Stage IV Uterine Sarcoma
• Uterine Carcinosarcoma
• Uterine Leiomyosarcoma
• Uterine Neoplasms

Intervention

Drug:
• ziv-aflibercept
Given IV

Locations

Country	Name	City	State
Canada	Juravinski Cancer Centre at Hamilton Health Sciences	Hamilton	Ontario
Canada	Cancer Centre of Southeastern Ontario at Kingston General Hospital	Kingston	Ontario
Canada	London Regional Cancer Program	London	Ontario
Canada	McGill University Department of Oncology	Montreal	Quebec
Canada	Odette Cancer Centre- Sunnybrook Health Sciences Centre	Toronto	Ontario
Canada	University Health Network-Princess Margaret Hospital	Toronto	Ontario
Canada	BCCA-Vancouver Cancer Centre	Vancouver	British Columbia
Canada	Vancouver General Hospital	Vancouver	British Columbia
United States	University of Michigan University Hospital	Ann Arbor	Michigan
United States	University of Chicago Comprehensive Cancer Center	Chicago	Illinois
United States	City of Hope	Duarte	California
United States	Evanston CCOP-NorthShore University HealthSystem	Evanston	Illinois
United States	University of Southern California	Los Angeles	California
United States	Peoria Gynecologic Oncology	Peoria	Illinois
United States	Fox Chase Cancer Center	Rockledge	Pennsylvania
United States	UC Davis Comprehensive Cancer Center	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate, Evaluated According to the RECIST Criteria		Up to 3 years	No
Primary	Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group)		6 months	No
Primary	Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Carcinosarcoma Group)		6 months	No
Secondary	Survival (Leiomyosarcoma Group)	Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.	Up to 3 years	No
Secondary	Survival (Carcinosarcoma Group)	Survival statistics will be estimated using the Kaplan-Meier method. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. 95% confidence intervals will be provided for estimates of interest where possible.	Up to 3 years	No